GlassScriptPhysician profile
Akil Hassam
NPI 1700198975
$1,582.36
in general payments reported to CMS, 2019-2025
19 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.85 · 2020: $87.14 · 2021: $151 · 2022: $196 · 2023: $214 · 2024: $603 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $222.12 | 2021-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $218.16 | 2024-2025 | Voquezna |
| Abbvie INC. | $207.81 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $163.77 | 2024-2025 | Dupixent |
| Pfizer INC. | $122.36 | 2020-2023 | |
| Genzyme Corporation | $100.07 | 2022-2024 | |
| Janssen Biotech, INC. | $93.23 | 2022-2025 | Tremfya, Stelara |
| Celgene Corporation | $82.48 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $79.77 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.02 | 2024-2025 | Xifaxan, Plenvu |
| Mallinckrodt Hospital Products INC. | $41.82 | 2024-2025 | Terlivaz |
| Boston Scientific Corporation | $38.77 | 2022-2025 | Axonics |
| Ipsen Biopharmaceuticals, INC | $30.41 | 2025 | Iqirvo |
| Novo Nordisk INC | $28.10 | 2025 | Wegovy |
| Redhill Biopharma INC. | $18.43 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.85 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.76 | 2024 | |
| Amgen INC. | $17.30 | 2025 | Uplizna |
| Stryker Corporation | $16.13 | 2025 | Neptune |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akil Hassam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.